CoChat

Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide

Mack, C. M., Smith, P. A., Athanacio, J. R., Xu, K., Wilson, J. K., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., Parkes, D. G. · 2011 · Diabetes, Obesity and Metabolism
Cited by 49

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims: Davalintide is a second‐generation amylinomimetic peptide possessing enhanced pharmacological properties over rat amylin to reduce food intake in preclinical models. The current experiments in rats describe additional glucoregulatory actions of davalintide consistent with amylin agonism, and explore the duration of action of these effects. Methods: Subcutaneous (SC) injection of davalintide slowed gastric emptying with equal potency to amylin (ED 50 's = 2.3 and 4.1 µg/kg). This effect was maintained for 8 h with davalintide, but not amylin. Intraperitoneal injection of davalintide also reduced food intake with a potency similar to amylin (ED 50 's = 5.0 and 11.3 µg/kg). Consistent with amylin agonism, davalintide (10 µg/kg, SC) suppressed the plasma glucagon response over 90 min following an intravenous arginine bolus in anaesthetized rats. The elimination t 1/2 of davalintide (200 µg/kg, SC) was 26 min, similar to the t 1/2 of amylin, suggesting that pharmacokinetic‐independent mechanisms contribute to davalintide's enhanced duration of action. Binding kinetic studies using 125 I davalintide revealed no appreciable dissociation from the amylin nucleus accumbens receptor after 7 h while 125 I rat amylin did dissociate from this receptor ( K off = 0.013/min). Sustained SC infusion of davalintide (275 µg/kg/day) or amylin (300) decreased plasma glucose after an oral glucose challenge at 2 weeks (by 27 and 31%) and suppressed gastric emptying at 3 weeks (by 29 and 47%), demonstrating durable glucoregulatory actions of both peptides. Conclusions: These data show glucoregulatory properties of davalintide consistent with amylin agonism and suggest that slowed receptor dissociation plays a role in davalintide's prolonged pharmacodynamic actions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01465.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 49

Metadata

Authors
Mack, C. M., Smith, P. A., Athanacio, J. R., Xu, K., Wilson, J. K., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-10-27
Volume
13
Issue
12
Pages
1105-1113
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2041263309
Cited by
49
References
9
FWCI
2.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01465.x
The paper
Mack, C. M., Smith, P. A., Athanacio, J. R., Xu, K., Wilson, J. K., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011). Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01465.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.